Veru Inc. (NASDAQ:VERU) Short Interest Up 14.3% in January

Veru Inc. (NASDAQ:VERU) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 14,620,000 shares, an increase of 14.3% from the January 15th total of 12,790,000 shares. Based on an average daily trading volume, of 2,950,000 shares, the short-interest ratio is currently 5.0 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VERU. Gladstone Institutional Advisory LLC grew its holdings in shares of Veru by 34.2% in the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after purchasing an additional 14,500 shares during the period. Weaver Consulting Group grew its stake in shares of Veru by 41.0% in the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock valued at $45,000 after buying an additional 20,280 shares during the period. Wells Fargo & Company MN grew its stake in shares of Veru by 37.1% in the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock valued at $49,000 after buying an additional 20,430 shares during the period. Integrated Wealth Concepts LLC increased its holdings in shares of Veru by 31.3% during the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock worth $56,000 after buying an additional 20,500 shares during the last quarter. Finally, Barclays PLC raised its position in Veru by 11.8% in the fourth quarter. Barclays PLC now owns 206,515 shares of the company’s stock valued at $134,000 after purchasing an additional 21,738 shares during the period. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on VERU shares. Oppenheimer reissued an “outperform” rating and set a $5.00 target price on shares of Veru in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Veru in a report on Thursday, January 2nd.

Veru Stock Performance

Shares of NASDAQ:VERU traded up $0.02 during midday trading on Friday, hitting $0.54. The company’s stock had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. The business’s 50 day simple moving average is $0.71 and its 200 day simple moving average is $0.77. Veru has a 12-month low of $0.40 and a 12-month high of $1.92. The company has a market cap of $79.24 million, a P/E ratio of -1.93 and a beta of -0.54.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%. On average, sell-side analysts predict that Veru will post -0.26 earnings per share for the current fiscal year.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.